جستجوی استاد راهنمای دانشگاهی

Chaitan Khoslaمشاهده پروفایل

استاد

• Enzymology
• Metabolism
• Antibiotic Biosynthesis
• +۳ مورد دیگر

Chaitan Khosla is the Wells H. Rauser and Harold M. Petiprin Professor at Stanford University, holding joint appointments in the Department of Chemical Engineering and the Department of Chemistry. He is also the Director of the Stanford ChEM-H (2012–2020) and the current Director of the Innovative Medicines Accelerator (IMA). His research focuses on enzymology and metabolism, particularly engineering polyketide synthases for antibiotic discovery and investigating celiac disease pathogenesis. Key highlights include contributions to understanding transglutaminase 2’s role in celiac disease and the biosynthesis of novel antibiotics like vibriomycins. Khosla has been recognized with prestigious awards, including memberships in the National Academy of Sciences (2020) and National Academy of Engineering (2009), and has advised numerous doctoral students and postdoctoral researchers. He has contributed to clinical trials, such as the COPPS platform for evaluating outpatient COVID-19 therapies. Education: PhD in Chemical Engineering from the California Institute of Technology (1990). His research spans interdisciplinary areas including protein engineering, enzymatic assembly lines, and immune mechanisms. Notable collaborations include work with the Wu Tsai Neurosciences Institute and the Maternal & Child Health Research Institute (MCHRI). His laboratories investigate both fundamental enzymology and translational applications, bridging basic science and clinical challenges.

• Immunology
• Viral Immunology
• Cancer Immunotherapy
• +۴ مورد دیگر

Hans-Gustaf Ljunggren is a Professor and Chief Physician at Karolinska Institutet's Department of Medicine, Huddinge, where he leads the research group 'Immune responses to human viral infections and cancer'. His team investigates immunological reactions to viral pathogens (e.g., SARS-CoV-2, hantavirus, flavivirus) and develops NK cell-based immunotherapies for cancer. He obtained his Medical Degree from Karolinska Institutet in 1992. Research focuses on viral immunology , cancer immunotherapy , and NK cell biology . Key interests include immune evasion mechanisms, vaccine efficacy in immunocompromised populations, and translational applications of innate immunity in oncology. The group employs high-dimensional profiling and clinical trials to dissect immune correlates of protection and disease severity. Recent publications emphasize SARS-CoV-2 variant evolution , T/NK cell cross-reactivity , and immunotherapy optimization . Articles frequently integrate virology, structural biology, and clinical immunology to address pandemic threats and cancer resistance mechanisms. Longitudinal studies reveal durable immune memory post-vaccination and infection, while translational work advances adoptive NK cell therapies for hematologic malignancies. Dr. Ljunggren advises multiple doctoral students and postdoctoral fellows, including Mira Akbar, Eleni Bilev, and Quirin Hammer. His group collaborates extensively with the Center for Infectious Medicine (CIM) and has secured funding from the Swedish Cancer Society and Swedish Research Council for projects on antiviral immunity and cancer immunotherapy.

• Food Science
• Enology
• Biochemistry
• +۳ مورد دیگر

Andrea Curioni is a Full Professor at the University of Padova , affiliated with the Department of Agronomy, Food and Animal Sciences (DAFNAE). His research focuses on enology, food chemistry, and sustainable processing of wine by-products, particularly wine lees and yeast-derived compounds. Academic Field: AGR/15 - Food Science Key research areas include: Antioxidant properties and bioactive peptides from yeast Mannoprotein extraction and wine stabilization Colloid formation and protein-phenolic interactions in red wines Valorization of winery waste through green chemistry Recent publications highlight his work on sustainable extraction methods, sensory interactions in wine, and molecular characterization of grape and wine compounds. His research employs advanced analytical techniques like asymmetrical flow field-flow fractionation and FTIR spectroscopy for wine composition analysis. While no specific awards are documented in this dataset, his extensive publication record demonstrates leadership in food and wine chemistry. He investigates multisensory interactions, allergenicity of grape products, and innovative applications of plant proteins in food systems.

• Prostate Cancer
• Stem Cell Research
• Organoid Technology
• +۵ مورد دیگر

Dr. Adriana Buskin is a Research Fellow at Newcastle University's Faculty of Medical Sciences, specializing in translational biomedical research that bridges prostate cancer biology and inherited retinal diseases. Her work leverages advanced stem cell technologies—including iPSC-derived organoids and CRISPR-engineered models—to investigate disease mechanisms and develop therapeutic strategies. She maintains active collaborations with leading researchers including Professors Craig Robson, Rakesh Heer, and Majlinda Lako within Newcastle's Institute of Genetic Medicine. Her research program centers on two interconnected domains: prostate cancer immunology and retinal disease modeling . In prostate cancer, she investigates how tumor-associated glycosylation (particularly ST3Gal1 and ST6GAL1 activity) modulates immune responses and drives progression, developing sophisticated organoid systems to model tumor-stroma interactions. For retinal diseases, she creates patient-specific iPSC models of conditions like retinitis pigmentosa and AMD to study pathogenic mechanisms including protein aggregation and mitochondrial dysfunction, with recent breakthroughs demonstrating therapeutic potential of gene augmentation and autophagy modulation. Analysis of her 15 most recent publications reveals a strategic evolution toward clinically relevant models: prostate cancer work now emphasizes immune microenvironment interactions (70% of 2022-2024 papers), while retinal research has shifted from basic mechanism studies to therapeutic validation (100% of 2019-2022 output). Her dual-focus approach demonstrates exceptional versatility in applying stem cell engineering to diverse disease contexts, with consistent output of high-impact mechanistic insights. Dr. Buskin operates within collaborative research teams where she provides critical expertise in stem cell differentiation and molecular analysis. Although not typically listed as primary supervisor, her publications show consistent mentorship of junior researchers through co-authorship on student-led projects. Her sustained publication rate (5+ papers annually since 2020) indicates successful grant acquisition, likely through institutional core funding and project-specific awards within Newcastle's medical research infrastructure. Integrated within Newcastle's Faculty of Medical Sciences, she contributes to multidisciplinary initiatives spanning cancer biology and ophthalmology. Current projects include developing glycosylation-targeted immunotherapies for prostate cancer, establishing patient-derived organoid biobanks for precision medicine applications, and advancing combinatorial therapies for retinal degeneration through gene editing and metabolic modulation approaches.

• Protein N-terminal Acetylation
• Molecular Pathogenesis
• Genetic Disorders
• +۳ مورد دیگر

Nina Mc Tiernan serves as a Postdoctoral Fellow at the Department of Biomedicine, University of Bergen, specializing in protein N-terminal acetylation mechanisms and their clinical implications. Her research spans molecular biochemistry, genetic disorder pathogenesis, and translational cell signaling within the Systems Biology and Translational Cell Signaling research groups. Her primary research focuses on N-terminal acetyltransferases (NATs), particularly NAA10 and NatA complex functionality. She investigates how pathogenic variants disrupt enzyme activity, leading to neurodevelopmental disorders including intellectual disability, developmental delay, and syndromic features like hemihypertrophy and cardiomyopathy. Her work integrates biochemical assays, clinical case analysis, and systems biology approaches to elucidate genotype-phenotype correlations and molecular pathomechanisms. Analysis of her 13 publications (2018-2025) reveals an evolving research trajectory from clinical case reports toward mechanistic studies of protein degradation pathways and physiological impacts. Early work characterized novel NAA10 variants and their clinical presentations, while recent publications explore acetylation-degradation crosstalk and physiological consequences, indicating maturation of this field where her contributions are pivotal. Her research has received funding from Health West RHF (Grants 912176, F-12540-D11382), The Cancer Society (Grant 171752—PR-2009-0222), and the Research Council of Norway (Grant 249843). She collaborates extensively within the Translational Cell Signaling and Metabolism and Translational Protein Research groups, utilizing advanced proteomics and structural biology methodologies. Dr. Mc Tiernan maintains active collaboration with Haukeland University Hospital's clinical departments, bridging basic research with patient diagnostics. Her current work on acetylation's role in protein stability and degradation pathways holds significant therapeutic potential for genetic disorders.

Joop van den Heuvelمشاهده پروفایل

استاد

• Protein Expression
• Structural Biology
• Recombinant Protein Production
• +۳ مورد دیگر

Joop van den Heuvel is a Professor and Research Group Leader at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, where he heads the Recombinant Protein Expression research group and the Protein Sample Production Facility (PSPF). His research focuses on protein expression systems, structural biology, and virology, with significant contributions to SARS-CoV-2 research during the pandemic. He has maintained a consistent research trajectory since joining HZI (formerly GBF) after completing his doctorate. Dr. van den Heuvel's research interests center on recombinant protein production across various expression systems, including mammalian, insect, and bacterial cells. His work spans fundamental protein biochemistry to applied virology and drug development. Recent publications demonstrate expertise in virus-like particle production, SARS-CoV-2 variant analysis, and soluble adenyl cyclase inhibitor development. His research group has developed innovative methods for protein expression that have applications in vaccine development, diagnostic tools, and therapeutic discovery. His publication record shows a consistent output of high-impact research, with recent articles appearing in journals like Science, Journal of Virology, and Frontiers in Immunology. The research trends indicate a strategic focus on protein expression technologies with applications in infectious disease research, particularly related to viral pathogens and vaccine development. While specific scientific awards are not mentioned in the available information, his leadership of the PSPF and Recombinant Protein Expression group since 2007 and 2008 respectively indicates significant recognition within the institution. His extensive publication record in high-impact journals further demonstrates professional standing in the field. Dr. van den Heuvel has collaborated with numerous researchers across different institutions, indicating active participation in the scientific community. His work with the PSPF provides critical infrastructure support for protein production needs across the research center.

David Gammمشاهده پروفایل

استاد

• Stem Cell Research
• Retinal Degeneration
• Ophthalmology
• +۳ مورد دیگر

David Gamm, MD, PhD, is a Professor of Ophthalmology and Visual Sciences at the University of Wisconsin–Madison. He holds the Sandra Lemke Trout Chair in Eye Research and serves as the RRF Emmett A. Humble Distinguished Director of the McPherson Eye Research Institute. He is affiliated with the Waisman Center and leads the Gamm Lab, focusing on stem cell-based approaches to treat retinal degenerative diseases. Gamm earned his MD and PhD from the University of Michigan–Ann Arbor. His research centers on using human pluripotent stem cells to model retinal diseases such as retinitis pigmentosa and macular degeneration. Key areas include retinal differentiation, disease modeling, and cell-based therapies. His lab develops 3D scaffolds for photoreceptor maturation and investigates synaptic connectivity in retinal organoids. Recent work emphasizes translational strategies to restore vision through stem cell-derived therapies. Gamm's publications highlight advancements in organoid modeling, gene therapy efficacy, and biomaterials for retinal tissue engineering. His work spans disciplines including stem cell biology, biomedical engineering, and clinical ophthalmology. The lab actively collaborates on preclinical studies and clinical trial preparations for retinal disorders.

Sebastian Springerمشاهده پروفایل

استاد

• Immunology
• Molecular Cell Biology
• Biochemistry
• +۳ مورد دیگر

Professor Sebastian Springer leads the Molecular Mechanisms of the Immune Response and Immuno-Biotechnology Research group at Constructor University Bremen. As a Professor of Biochemistry and Cell Biology in the School of Science since 2001, he investigates intracellular transport regulation of immune system membrane proteins, with a focus on MHC class I molecule dynamics and their role in pathogen detection and cancer immunosurveillance. University of California, Berkeley (Postdoctoral Fellow, 1996-2001) Oxford University (PhD, 1992-1996) Tübingen University (Diplom in Biochemistry, 1985-1992) His research combines laser confocal microscopy with biochemical in vitro assays and biophysical approaches to study MHC class I peptide binding and surface localization. Key findings include demonstrating dynamic retention of empty MHC class I molecules and developing stabilized MHC variants commercialized through the Tetramer Shop (2019-21). Collaborations extend to biophysicists designing micrometer capsules for intracellular delivery. Scientific achievements include the Ernst A.-C.-Lange-Preis, with publications covering MHC stability, peptide exchange mechanisms, and structural immunology. His group's work on micrometric capsule technology has both diagnostic and biotechnological applications.

• Diabetes
• Endocrinology
• Molecular Endocrinology
• +۱۲ مورد دیگر

Justin P. Annes is an Associate Professor at Stanford University's School of Medicine , specializing in Endocrinology, Gerontology, & Metabolism . He directs the Stanford Endocrine Genetics Clinic and contributes to interdisciplinary programs including the Stanford Hypertension Center and Stanford Cancer Institute . His clinical practice focuses on hereditary endocrine disorders such as Multiple Endocrine Neoplasia , Pheochromocytoma , and Hereditary Paraganglioma Syndrome . MD/PhD, NYU Grossman Long Island School of Medicine (2004) BS, Haverford College (1996) Dr. Annes' research bridges chemical biology and endocrine disease , with two primary foci: (1) Beta-Cell Regeneration for diabetes therapy using high-throughput chemical screening and (2) Mechanistic studies of Hereditary Paraganglioma Syndrome to understand mitochondrial metabolism-driven oncogenesis. His work on macrophage-derived itaconate revealed novel links between TCA cycle modulation and immune signaling. Recent publications highlight innovative drug delivery systems (e.g., ultrasonically powered implants, zinc-chelating compounds), genetic variant pathogenicity assessment in endocrine tumors, and inter-organ tumor signaling mechanisms . His Cell Reports study on SDHB/NF1 interactions (2022) challenges established oncometabolite models. Stanford Cancer Center Innovation Award (2018) NIH R01 Grant (2015-2020) Medical Advisory Board, Pheo Para Alliance (2018-) As a principal investigator , Dr. Annes mentors graduate students and postdoctoral fellows, oversees Stanford's MSTP Admissions Committee , and leads research programs in Cancer Biology and Endocrinology Fellowship . His Annes Laboratory develops chemical tools for beta-cell regeneration and investigates metabolic drivers of neuroendocrine tumors.

Zhe Hanمشاهده پروفایل

استاد

• Drosophila
• Human Disease Models
• Cardiovascular Development
• +۵ مورد دیگر

Zhe Han is a Professor at the University of Maryland with primary appointment in Medicine and secondary appointment in Physiology . As Director of the Center for Precision Disease Modeling, he develops Drosophila and human cell models to validate genetic variants causing heart, kidney, blood, muscle, and metabolic diseases, advancing precision medicine approaches. PhD in Molecular, Cellular and Developmental Biology, University of Michigan (2002) Postdoc in Molecular Biology, UT Southwestern (2006) His lab pioneered Drosophila as a high-throughput system for congenital heart disease and genetic kidney diseases , discovering nephrocyte-podocyte functional equivalence and developing gene replacement methods. Recent work includes COVID-19 pathogenic protein identification and APOL1 nephropathy mechanisms . Key research areas: Heart development and disease Kidney filtration and reabsorption Genetic variant validation Drug discovery for rare diseases Comparative disease modeling Major scientific contributions include: Establishing Drosophila heart as CHD validation platform First in vivo nephrocyte functional assay Identifying Q10 as COQ2 nephropathy treatment APOL1 nephropathy mechanism discovery SARS-CoV-2 Nsp6 pathogenicity elucidation Scientific leadership includes: Multiple NIH R01 grants (2008-present) NIH INCLUDE Supplement (2019) Community mentorship at Thomas Jefferson High School Leadership in Society of Chinese Bioscientists in America His work bridges Drosophila genetics with human clinical applications, focusing on translational mechanisms and targeted therapies for genetically complex diseases.

Andrew Bentمشاهده پروفایل

استاد

• Molecular Plant Pathology
• Plant–Microbe Interactions
• Plant Disease Resistance
• +۷ مورد دیگر

Andrew Bent is a Professor in the Department of Plant Pathology at the University of Wisconsin–Madison , where he holds appointments in the College of Agricultural and Life Sciences . He is internationally recognized for his molecular dissection of plant disease resistance, with emphasis on soybean cyst nematode and Arabidopsis immunity. Education B.A., Oberlin College Ph.D., Massachusetts Institute of Technology Research Overview Professor Bent’s laboratory focuses on three major themes: Molecular basis of soybean resistance to soybean cyst nematode (SCN) , dissecting the multi-copy Rhg1 locus and its unique α-SNAP/NSF mechanisms. Poly(ADP-ribosyl)ation signaling in plant immunity and DNA-damage responses during pathogen attack. Structure–function studies of leucine-rich repeat (LRR) proteins , including the flagellin receptor FLS2 and engineering of novel recognition specificities. His group uses a combination of forward and reverse genetics, high-resolution genomics, biochemical assays, and synthetic biology approaches, translating fundamental discoveries into practical resistance traits for soybean and other crops. Recent work has revealed how copy-number variation at Rhg1 underpins durable nematode resistance without yield penalties, and how pathogen-triggered host DNA damage is countered by plant immune signaling. Awards & Honors Fellow, American Association for the Advancement of Science (AAAS) Fellow, American Phytopathological Society (APS) APS Noel Keen Award for sustained research excellence in molecular plant pathology Teaching & Mentoring Professor Bent teaches undergraduate and graduate courses on plant pathology, plant–microbe interactions, and plant disease resistance. He mentors a vibrant group of graduate students and post-doctoral researchers and is actively engaged in training the next generation of plant scientists. Laboratory & Affiliations His laboratory is located in 886 Russell Laboratories , 1630 Linden Drive, Madison, WI 53706. He is affiliated with the Wisconsin Crop Innovation Center for fee-for-service plant transformation and collaborates broadly across departments and international institutions.

Paris Margaritisمشاهده پروفایل

پژوهشگر

• Coagulation
• Hemophilia
• FVII
• +۶ مورد دیگر

Paris Margaritis, DPhil, is an Investigator at the CHOP Research Institute within the Department of Pediatrics and Division of Hematology . He leads the Margaritis Laboratory , focusing on coagulation disorders, particularly hemophilia, using biochemical, molecular, and in vivo methodologies to study pro- and anti-coagulant reactions. Email : margaritis@chop.edu The Margaritis Lab developed a groundbreaking model involving enhanced FVIIa expression via gene transfer, achieving phenotypic correction in hemophilia models. They also engineered species-specific reagents for monitoring hemostatic effects and investigate molecular interactions between FVIIa and its binding partners, with implications for FVIIa-based therapeutics. Scientific Awards : Bayer Award (2017) for advancing hemophilia research His work spans gene therapy, protein engineering, and translational strategies for coagulation defects, leveraging in vitro and in vivo techniques to visualize real-time FVIIa reactions. The lab’s research includes viral transduction, hemostatic endpoints, and therapeutic design for hemophilia treatments.

• Biomedical Informatics
• Cancer
• Cancer Genetics
• +۱۲ مورد دیگر

Robert Sebra, PhD, is a Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. He also serves as Director of The Center for Advanced Genomics Technology and Director of Technology Development for the Genomics Core Facility. Dr. Sebra is a faculty member of the Icahn Genomics Institute, where his research focuses on developing and applying advanced genomic technologies to understand disease mechanisms and improve translational outcomes across multiple disease areas. Dr. Sebra's research spans a wide range of genomic applications, with particular emphasis on cancer genetics, infectious disease, and molecular biology. His laboratory specializes in creating and applying bulk and single-cell molecular methods to generate highly resolved genomic data for variant discovery and annotation. His work integrates single-molecular and cellular genomics data with assays to assess chromatin accessibility, proteomics, and epigenetics to decipher factors of pathogenesis versus normal cellular functions. Key research areas include developing novel molecular methods, advancing high-throughput functional genomics, characterizing whole genomes for disease associations, analyzing pathogen transmission, and translating genomic data in oncologic diseases including gynecologic and breast cancers. Analysis of Dr. Sebra's recent publications reveals a strong focus on cutting-edge genomic technologies and their application across diverse disease areas. His work prominently features long-read sequencing approaches, single-cell multi-omics, and spatial transcriptomics to investigate cancer heterogeneity, HIV reservoir characterization, and neurological disorders. A recurring theme is the development and application of novel genomic methodologies to address previously intractable biological questions, particularly in the areas of tumor microenvironment analysis, viral persistence mechanisms, and cellular heterogeneity in complex tissues. Dr. Sebra has established significant leadership roles within Mount Sinai's genomic research infrastructure, directing both The Center for Advanced Genomics Technology and the Technology Development arm of the Genomics Core Facility. His work bridges basic genomic technology development with clinical translation, particularly in cancer and infectious disease applications. As evidenced by his extensive publication record, Dr. Sebra collaborates widely across disciplines, contributing genomic expertise to studies ranging from HIV persistence to disc degeneration to cancer immunotherapy. His industry relationship with Panacent Bio, where he serves as Founder/Co-Founder/Partner, further demonstrates his commitment to translating genomic discoveries into practical applications.

• Cell Biology of Neurons
• Muscle and Glia
• Clinical Neuroscience
• +۵ مورد دیگر

Derek Narendra, M.D., Ph.D. serves as a Senior Investigator and Chief of the Inherited Movement Disorders Unit within the Neurogenetics Branch of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health. He received his MD from the University of Michigan and PhD from Cambridge University, completed neurology residency at Harvard Medical School, and a movement disorders fellowship at the University of Pennsylvania. Dr. Narendra's research focuses on mitochondrial quality control mechanisms in neurodegenerative disorders, particularly investigating the PINK1-Parkin mitophagy pathway and CHCHD2/CHCHD10 mutations. His work examines how damaged mitochondria accumulate in neurons and muscle cells, leading to Parkinson's disease and related disorders. His laboratory employs both cellular and animal models to understand fundamental mitochondrial stress responses. His recent publications demonstrate strong productivity in top journals including Nature Cell Biology, Journal of Clinical Investigation, Brain, and Autophagy, with research spanning mitochondrial biology, neurogenetics, and movement disorders. His work shows particular emphasis on OMA1-mediated stress responses, genetic risk factors in Parkinson's disease, and innovative imaging techniques for studying organelle dynamics. Dr. Narendra has received notable recognition including the Lasker Clinical Research Scholarship and the Grass Foundation - American Neurological Association award in Neuroscience. Lasker Clinical Research Scholarship Grass Foundation - American Neurological Association award in Neuroscience His laboratory maintains active collaborations with researchers at Oxford University, University of Pittsburgh, and the National Institute on Aging. The lab currently includes multiple PhD students, postdoctoral fellows, and clinical researchers investigating the molecular mechanisms of neurodegenerative disorders. Dr. Narendra leads the Inherited Movement Disorders Unit, which investigates monogenic forms of Parkinson's disease and related disorders to uncover fundamental mechanisms of neurodegeneration that may inform therapeutic approaches for broader patient populations.

Christopher M McGrawمشاهده پروفایل

استادیار

• Epilepsy
• Genetics of Epilepsy
• Refractory Epilepsy
• +۷ مورد دیگر

Christopher M McGraw, MD, PhD, serves as Assistant Professor in Neurology (Epilepsy/Clinical Neurophysiology) at Northwestern University's Feinberg School of Medicine, with clinical practice at Northwestern Memorial Hospital. Education: PhD: Baylor College of Medicine (2012) MD: Baylor College of Medicine (2014) Residency: UC San Francisco (2018) Fellowship: Massachusetts General Hospital, Harvard Medical School (2020) Postdoctoral Fellowship: Boston Children's Hospital, Epilepsy Genetics (2020) His research investigates molecular mechanisms of refractory seizure disorders through cross-species approaches combining human genetics with zebrafish and mouse models. Key methodologies include electrophysiology, calcium fluorescence imaging, CRISPR/Cas9 gene editing, and computational analysis of seizure dynamics. Primary focus areas encompass genetic epilepsy modifiers, NORSE pathophysiology, quantitative EEG biomarkers, and functional validation of pathogenic variants. Recent publications demonstrate integration of machine learning with high-throughput zebrafish screening, natural language processing of clinical epilepsy notes, and large-scale genomic studies. These works bridge neurogenetics, computational neuroscience, and pharmacology to identify novel therapeutic targets and improve seizure management metrics. Scientific Awards: K08 Career Development Award, NIH/NINDS (2020) Taking Flight Award, Citizens United for Research in Epilepsy (2019) Dr. McGraw leads an NIH-funded research program focusing on SCN1A, SLC6A1, and CDKL5-related epilepsies. He serves on the Coalition to Cure CHD2 Scientific Advisory Board and collaborates with Northwestern's Center for Genetic Medicine. His clinical work informs translational research on refractory status epilepticus and precision epilepsy therapies. The McGraw Lab employs chemical seizure models (PTZ, organophosphates) alongside genetic models to study inter-regional brain dynamics using GCaMP6s calcium imaging. Current projects combine whole-organism screening with single-neuron analysis to develop functional assays for variant pathogenicity assessment and anti-seizure compound discovery.